XVIVO Perfusion launches Perfadex Plus, an upgraded ready to use version of Perfadex
XVIVO Perfusion has spent nearly five years developing a ready to use version of its´ product for cold preservation of lungs. The new upgraded version of Perfadex is named Perfadex Plus and the company has filed for patent for Perfadex Plus. It is currently being launched in European countries and is expected to be available in all major markets within 12 months.
Perfadex is the market gold standard and has been marketed by XVIVO Perfusion since 1999. It is used for cold preservation of lungs i.e. flushing away donor blood and preserving the donated lungs before transplantation. It is being used in an overwhelming majority of all lung transplantations performed in the world and is estimated to have a worldwide market share of around 90 percent.
XVIVO Perfusion has through formulation development upgraded the product so that it now can be used without prior addition and mixing of buffer and electrolyte. Patent applications has been filed for the new proprietary formulation which has been named Perfadex Plus. Perfadex Plus is presently being launched with a start in European countries and is expected to be available in all major markets within the next 12 months.
“We are very happy to be able to offer the clinics a new safer, and easier to use version of our market gold standard product for lung preservation, Perfadex Plus, which will save time and effort for the teams that go out and retrieve donated lungs” says XVIVO Perfusion CEO Magnus Nilsson.
June 5, 2018
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, email@example.com
Magnus Nilsson, CEO, +46 31 788 2150, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 am CET on June 5, 2018.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com